Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 5

High mobility group box- 1 levels may be associated with disease activity of Behcet’s disease

Sayfa
2690–2697
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Key words: High mobility group box- 1, autoimmune diseases, Behcet’s disease, inflammation

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: High mobility group box- 1 (HMGB- 1) is a nuclear protein acting as a proinflammatory molecule.
📊
Temel Bulgular & Veri:The serum HMGB- 1 levels were found elevated in chronic inflammatory diseases.
💡
Sonuç & Katkı:Key words: High mobility group box- 1, autoimmune diseases, Behcet’s disease, inflammation
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: High mobility group box- 1 (HMGB- 1) is a nuclear protein acting as a proinflammatory molecule. The serum HMGB- 1 levels were found elevated in chronic inflammatory diseases. In this cross-sectional study, serum HMGB- 1 levels in Behcet’s disease (BD) patients and healthy controls (HC) were studied. Also, its association with disease activity scores and clinical findings were evaluated. Materials and methods: Ninety BD patients and 50 age-sex matched HC were included in the study. Disease activity scores were assessed by Behcet Disease Current Activity Form (BDCAF) and Behcet Syndrome Activity Score (BSAS). Serum HMGB- 1 levels were measured using a commercial ELISA kit. A p value of < 0.05 was considered to be statistically significant. Results: Serum HMGB- 1 levels were significantly higher in BD than in HC (43.26 pg/mL and 16.73 pg/mL; p < 0.001, respectively). Serum HMGB- 1 levels were statistically significantly associated with presence of erythema nodosum (EN) and genital ulcers in the last one month prior to recruitment (p = 0.041 and p < 0.001, respectively). BDCAF and BSAS scores were positively correlated with serum HMGB- 1 level ( p = 0.03 and p = 0.02, respectively). Conclusion: HMGB - 1 may play a role in the development of BD. Also, due to its positive correlation with disease activity indices, it can be used as a novel disease activity parameter in BD. Key words: High mobility group box- 1, autoimmune diseases, Behcet’s disease, inflammation

🔖

Bu Makaleye Atıf Yap

TURGAY, T. M., YAYLA, M. E., TORGUTALP, M., OKATAN, İ. E., KINIKLI, G., EROĞLU, D. Ş., SEZER, S., DİNÇER, A. B. K., GÜLÖKSÜZ, E. G. A., YÜKSEL, M. L., ATEŞ, A., GÜLER, D. D., GÜLER, H. S., KARAHAN, Z. C. (2022). High mobility group box- 1 levels may be associated with disease activity of Behcet’s disease. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 5, 2690–2697. https://ajindex.com/articles/609561

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Davatchi F. Behçet’s disease. International journal of rheumatic diseases 2018
  2. 21 (12): 2057. doi: 10.1111/1756-185X.13465 2. de Chambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet’s disease. Autoimmunity reviews 2012
  3. 11 (10): 687-98. doi: 10.1016/j. autrev.2011.11.026 3. Lee S, Kwak MS, Kim S, Shin J-S. The role of high mobility group box 1 in innate immunity. Yonsei medical journal 2014
  4. 55 (5): 1165-76. doi: 10.3349/ymj.2014.55.5.1165 4. Pilzweger C, Holdenrieder S. Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases. Diagnostics 2015
  5. 5 (2): 219-53. doi: 10.3390/ diagnostics5020219 5. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer research 2002
  6. 62 (16): 4805- 11. doi: Published August 2002 6. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. The Journal of biological chemistry 2004
  7. 279 (9): 7370-7. doi: 10.1074/jbc.M306793200 7. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. American journal of physiology Cell physiology 2006
  8. 290 (3): C917-24. doi: 10.1152/ ajpcell.00401.2005 8. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007
  9. 110 (6): 1970-81. doi: 10.1182/blood-2006-09-044776 9. Kang R, Chen R, Zhang Q, Hou W, Wu S et al. HMGB1 in health and disease. Molecular aspects of medicine 2014
  10. doi: 10.1016/j.mam.2014.05.001 10. Andersson U, Wang H, Palmblad K, Aveberger A-C, Bloom O et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine 2000
  11. 192 (4): 565-70. doi: 10.1084/jem.192.4.565 11. Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis & Rheumatism 2008
  12. 58 (9): 2675-85. doi: 10.1002/ art.23729 12. Ma C-y, Jiao Y-l, Zhang J, Yang Q-r, Zhang Z-f et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in syste